Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot

Hansa Biopharma has encouraging early clinical results showing its drug imlifidase, used as a pretreatment, enabled Duchenne muscular dystrophy patients to receive the gene therapy Elevidys. Sarepta is searching for ways to mitigate excessive immune responses to Elevidys that can lead to serious and potentially fatal liver injury. The post Sarepta’s Future in Gene Therapy…

Read More

Why Biogen Is Paying $5.6B to Buy Apellis Pharma

Biogen’s Apellis Pharmaceuticals acquisition comes nearly two years after the drugmaker purchased immunology startup Human Immunology Biosciences. CEO Chris Viehbacher said Apellis accelerates Biogen’s expansion in nephrology, supporting a HI-Bio drug currently in pivotal testing for three kidney conditions. The post Why Biogen Is Paying $5.6B to Buy Apellis Pharma appeared first on MedCity News.

Read More

Silence in Sikeston: Is There a Cure for Racism?

SIKESTON, Mo. — In the summer of 2021, Sikeston residents organized the biggest Juneteenth party in the city’s history. Sikeston police officers came too, both to provide security for the event and to try to build bridges with the community. But after decades of mistrust, some residents questioned their motives.  In the series finale of…

Read More

THCB Gang — DiME Special Episode 141, Thursday October 24

Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday October 24 at 1pm PST 4pm EST are Digital Medicine Society CEO Jennifer Goldsack, (@GoldsackJen) , the VA’s Cole Zanetti (@ColeZanetti); and the Chief Commercial Officer at Curai Health Nicole Bell (@bellnicolee). There’ll likely be chatter about #HLTH2024 but also a lot of focus on the new…

Read More